← All trials
NCT04985435
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2021
- Primary completion
- Mar 31, 2023
- Completion date
- Apr 30, 2023
- First posted
- Aug 2, 2021
- Last posted
- Aug 2, 2021
- Enrollment
- 100
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rheumatology Research Center Northern NetherlandsLead sponsor
- Leiden UniversityCollaborator
- Galapagos NVCollaborator
- Medical Center LeeuwardenCollaborator
- Rheumatology Research Center Northern NetherlandsSponsor investigator
- Rheumatology Research Center Northern NetherlandsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.